Biotechnology plays a crucial role in driving America’s economic growth. The U.S. has effectively led the world in turning scientific innovations into life-saving therapies.
This leadership isn’t merely a result of government directives. It stems from an environment where risk is recognized and rewarded, where intellectual property is safeguarded, and private markets—and not government entities—dictate what patients receive.
Yet, this foundational support is now under threat. Interestingly, it’s not Beijing that’s the main concern for American biotechnology dominance; it seems to be Washington itself. Recent policy shifts indicate a movement from market principles toward more direct regulation and oversight.
Recent initiatives, such as the Inflation Reduction Act, empower Medicare to set drug prices. Just recently, an executive order from the White House tried to link U.S. drug pricing more closely with countries where government systems control expenses through strict caps and distribution methods.
And, as if that weren’t enough, there are proposals for imposing 100% tariffs on imported drugs, which could complicate matters further. The idea is to use pricing models from specific Pfizer drugs to justify lower tariffs.
While these moves might appear appealing from a political standpoint, their economic consequences are significant and largely detrimental.
A survey from the National Bureau of Economic Research indicates that a drop in anticipated drug prices could lead to a substantial decrease in early-stage research and development, thereby reducing new treatment options. This inevitably results in longer wait times for patients, meaning Americans may end up waiting longer for the very innovations developed by their own companies.
Currently, the federal government already oversees about 60% of all medical costs. This situation does not represent a healthy market. Instead, it’s a hybrid framework where the government influences costs through subsidies and regulations, leading to unsatisfactory outcomes.
Meanwhile, as Washington tightens its grip, China is capitalizing on opportunities. Their “Made in China 2025” initiative has identified biotechnology as a strategic area of focus.
Back in 2009, China accounted for just 1% of global Phase I through III clinical trials, but by 2024, that figure had increased to 30%. Meanwhile, the U.S. share dipped from 39% to 35%. At this rate, China may well surpass the U.S. in clinical trials by 2027.
This isn’t just a statistical trend; it symbolizes leadership in science, investor confidence, and access to new innovations. If clinical trials continue shifting away from the U.S., Americans face diminished opportunities for groundbreaking treatments.
Add to that China’s growing advantage in STEM education. In 2020, China produced over 338,000 advanced STEM degrees, compared to just 221,000 in the U.S.. This gap appears to be widening, and if current trends persist, by 2040, China could potentially graduate more than double the number of advanced STEM graduates each year compared to the U.S.
Drug approvals may also suffer under tighter price control measures. The U.S. currently sees around 55-60 new active substances approved annually. However, under policies like the Inflation Reduction Act, this could drop to below 30.
In the meantime, China is ramping up its efforts to surpass U.S. leadership. If the current course continues, the U.S. might find itself stifling innovation while Washington remains stagnant.
The interconnected issues—declining trial participation, a surge in Chinese STEM talent, reduced R&D investment, and fewer drug approvals—paint a troubling picture. If the U.S. doesn’t change its trajectory, it risks losing its biotechnology edge due to mismanagement rather than direct competition from China.
The core issue isn’t market failure; it’s a failure of governance. The remedy lies not in more command-and-control policies but rather in revisiting the free market principles that once fueled innovation.
Developing biotechnology is costly, with estimates of over $2 billion per drug and timelines stretching beyond a decade. Most efforts don’t yield success. Investors are drawn to this field by the potential for returns, which allows them to reinvest in future innovations. Remove that incentive, and the field risks stagnation.
History offers a cautionary tale: Europe’s attempts to control prices have led to long waits for new treatments, and many promising options never reach the market. This isn’t a scenario the U.S. can afford to replicate.
Biotechnology isn’t merely a luxury sector; it’s vital for advancing healthcare and holds strategic significance. The next breakthrough for diseases like cancer or Alzheimer’s could well be originating from within the U.S.
The U.S. faces a choice: continue to lead in innovation and public health or impose stricter government controls, leading to delays and diminishing leadership in the industry. The world, along with investors and patients, is watching closely. Will Washington act before it’s too late?
